NYSE: BMYBristol Myers Squibb Co Stock
$62.00-0.11 (-0.18%)
Updated Sep 15, 2021
BMY Price
$62.00
Fair Value Price
N/A
Market Cap
$137.77B
52 Week Low
$56.75
52 Week High
$69.75
P/E
-27.68x
P/B
3.74x
P/S
3.36x
PEG
N/A
Dividend Yield
3.1%
Revenue
$44.38B
Earnings
-$5.08B
Gross Margin
75.9%
Operating Margin
-9.31%
Profit Margin
-11.4%
Debt to Equity
2.01
Operating Cash Flow
$13B
Beta
0.65
Next Earnings
Oct 27, 2021
Ex-Dividend
Sep 30, 2021
Next Dividend
Nov 1, 2021
Zen Score
High
Medium
Low
31
Industry average
Reasons for this score
BMY is good value based on its book value relative to its share price (3.74x), compared to the US Drug Manufacturers - General industry average (5.17x)
Valuation
BMY's Earnings (EBIT) of -$4.13B are insufficient to safely cover interest payments on company debt ($45.16B)
Financials
BMY's profit margin has decreased (-9.8%) in the last year from (-1.6%) to (-11.4%)
Financials
BMY News
Valuation
BMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.68x
Industry
21.95x
Market
-8.74x
BMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.74x
Industry
5.17x
BMY is good value based on its book value relative to its share price (3.74x), compared to the US Drug Manufacturers - General industry average (5.17x)
Valuation
BMY's financial health
Profit margin
Revenue
$11.7B
Net Income
$1.1B
Profit Margin
9%
BMY's Earnings (EBIT) of -$4.13B are insufficient to safely cover interest payments on company debt ($45.16B)
Financials
BMY's profit margin has decreased (-9.8%) in the last year from (-1.6%) to (-11.4%)
Financials
Assets to liabilities
Assets
$110.8B
Liabilities
$73.9B
Debt to equity
1.23
BMY's short-term assets ($29.16B) exceed its short-term liabilities ($18.99B)
Financials
BMY's long-term liabilities ($54.93B) exceed its short-term assets ($29.16B)
Financials
BMY's debt has increased relative to shareholder equity (2.01), over the past 5 years ago (1.19)
Financials
BMY's debt to equity ratio (2.01) is considered high
Financials
Cash flow
Operating
$3.1B
Investing
$180.0M
Financing
-$3.2B
BMY's operating cash flow ($12.77B) is sufficient to service the company's debt ($45.16B)
Financials
Bristol Myers Squibb Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.